NCT03017131 2026-04-06Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube CancerRoswell Park Cancer InstitutePhase 1 Active not recruiting9 enrolled